Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ketamine Biomarker Validation
Sponsor: Soterix Medical
Summary
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
Official title: EEG Biomarker Development for Ketamine Administration
Key Details
Gender
All
Age Range
18 Years - 59 Years
Study Type
INTERVENTIONAL
Enrollment
0
Start Date
2025-12-20
Completion Date
2028-03-01
Last Updated
2026-10-19
Healthy Volunteers
No
Conditions
Interventions
Ketamine (0.25 mg/kg)
Low level ketamine infusion therapy.
Ketamine (0.5 mg/kg)
Medium level ketamine infusion therapy.
Ketamine (0.75 mg/kg)
High level ketamine infusion therapy.
Locations (1)
Columbia University Irving Medical Center
New York, New York, United States